This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Dullens, H. F. J. Articles by Otter, W. D. Search for Related Content PubMed PubMed Citation Articles by Dullens, H. F. J. Articles by Otter, W. D.

Therapy with Allogeneic Immune Peritoneal Cells¹

Department of Pathology, State University, Pasteurstraat 2, Utrecht, The Netherlands

The growth-inhibitory effect in vivo of murine allogeneic immune peritoneal cells (C57BL versus SL2 lymphoma cells) on SL2 lymphoma cells injected i.p. into the syngeneic recipient (DBA/2 mouse) was studied. The peak value of immunity and the peak value of the growth-inhibitory effect in vitro was reached 9 days after immunization.

In 2 of 5 mice (survival time, 37 and 68 days), 2 x 10⁶ SL2 lymphoma cells were eradicated by 1 i.p. injection of 2 x 10⁶ C57BL allogeneic immune peritoneal macrophages (plus contaminating lymphocytes) obtained 9 days after immunization. In 4 of 5 DBA/2 mice, 2 x 10⁶ SL2 cells were eradicated with three successive i.p. injections of 2 x 10⁶ C57BL allogeneic immune peritoneal macrophages (plus lymphocytes) collected 10 days after immunization (survival time, 200 days; at this time of survival the experiment was stopped).

Immune peritoneal lymphocytes, normally contaminating 2 x 10⁶ macrophages, did not inhibit growth of lymphoma cells in vivo. However, 2 x 10⁶ immune peritoneal macrophages, freed of contaminating lymphocytes, caused a slight inhibition of growth of lymphoma cells in vivo.

Peritoneal cells from C57BL mice immunized against DBA/2 liver cells or against CBA-derived TLC5 lymphoma cells were not capable of eradicating SL2 lymphoma cells in DBA/2 mice.

¹ This investigation was supported by the State University Utrecht, The Netherlands, and by a grant of the Koningin Wilhelmina Fonds, National Fund for Investigation of Cancer.

Received 6/ 1/73. Accepted 3/26/74.